277 related articles for article (PubMed ID: 16680126)
41. Upping the ante on antibodies.
Baker M
Nat Biotechnol; 2005 Sep; 23(9):1065-72. PubMed ID: 16151393
[TBL] [Abstract][Full Text] [Related]
42. Small is the big issue: micromoulding.
Rankin A; Manser P
Med Device Technol; 2002 Dec; 13(10):18-20. PubMed ID: 12575523
[TBL] [Abstract][Full Text] [Related]
43. Biopharmaceutical proteins: opportunities and challenges.
Birch JR; Onakunle Y
Methods Mol Biol; 2005; 308():1-16. PubMed ID: 16082021
[No Abstract] [Full Text] [Related]
44. The challenges of product- and process-related impurities to an evolving biopharmaceutical industry.
Bracewell DG; Smales CM
Bioanalysis; 2013 Jan; 5(2):123-6. PubMed ID: 23330553
[No Abstract] [Full Text] [Related]
45. Genesis IV--Fourth London Biotechnology Conference.
Chan D
IDrugs; 2005 Jan; 8(1):34-6. PubMed ID: 15650939
[No Abstract] [Full Text] [Related]
46. The business of making vaccines.
Sheridan C
Nat Biotechnol; 2005 Nov; 23(11):1359-66. PubMed ID: 16273061
[TBL] [Abstract][Full Text] [Related]
47. In-process testing and limits.
Sjöholm I
Dev Biol Stand; 1997; 91():73-8. PubMed ID: 9413685
[No Abstract] [Full Text] [Related]
48. Connecting genes, drugs and diseases.
Weinstein JN; Pommier Y
Nat Biotechnol; 2006 Nov; 24(11):1365-6. PubMed ID: 17093484
[No Abstract] [Full Text] [Related]
49. The impact of bacteriophage genomics.
McGrath S; Fitzgerald GF; van Sinderen D
Curr Opin Biotechnol; 2004 Apr; 15(2):94-9. PubMed ID: 15081045
[TBL] [Abstract][Full Text] [Related]
50. Pharmacogenetics--pivotal to the future of the biopharmaceutical industry.
Foot E; Kleyn D; Palmer Foster E
Drug Discov Today; 2010 May; 15(9-10):325-7. PubMed ID: 20298799
[No Abstract] [Full Text] [Related]
51. A united front.
Nature; 2011 Apr; 472(7344):389-90. PubMed ID: 21525888
[No Abstract] [Full Text] [Related]
52. Graduate Education in Pharmacology: Addressing the need for specialized training for pharmaceutical and biotechnology careers.
Barrett JE; McGonigle P; Clark JE
Pharmacol Res; 2016 Nov; 113(Pt A):327-331. PubMed ID: 27590782
[No Abstract] [Full Text] [Related]
53. PDA Single-Use Systems Cross-Organizational Workshop-Meeting Summary, May 14, 2014-PDA Global Headquarters, Bethesda, MD.
Repetto R; Levy R
PDA J Pharm Sci Technol; 2015; 69(2):317-25. PubMed ID: 25868997
[TBL] [Abstract][Full Text] [Related]
54. Raw material considerations.
Lubiniecki AS; Shadle PJ
Dev Biol Stand; 1997; 91():65-72. PubMed ID: 9413684
[TBL] [Abstract][Full Text] [Related]
55. An interview with Paul England, Ph.D., ProXara Biotechnology, Ltd. Interviewed by Vicki Glaser.
England P
Assay Drug Dev Technol; 2004 Apr; 2(2):115-20. PubMed ID: 15165507
[No Abstract] [Full Text] [Related]
56. Survey results on the use of the tissue cross-reactivity immunohistochemistry assay.
Bussiere JL; Leach MW; Price KD; Mounho BJ; Lightfoot-Dunn R
Regul Toxicol Pharmacol; 2011 Apr; 59(3):493-502. PubMed ID: 20951178
[TBL] [Abstract][Full Text] [Related]
57. Biopharmaceuticals in China.
Hu X; Ma Q; Zhang S
Biotechnol J; 2006 Nov; 1(11):1215-24. PubMed ID: 17089435
[TBL] [Abstract][Full Text] [Related]
58. Drug discovery: past, present and future.
Malik NN
Drug Discov Today; 2008 Nov; 13(21-22):909-12. PubMed ID: 18852066
[No Abstract] [Full Text] [Related]
59. BCG report rosy on genomics.
Fletcher L
Nat Biotechnol; 2001 Aug; 19(8):703. PubMed ID: 11491102
[No Abstract] [Full Text] [Related]
60. Manufacturing of biopharmaceuticals and implications for biosimilars.
Wurm FM
Kidney Blood Press Res; 2007; 30 Suppl 1():6-8. PubMed ID: 17726336
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
